FMP
Lantheus Holdings, Inc.
LNTH
NASDAQ
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
91.47 USD
-0.11 (-0.12%)
2023
2022
2021
2020
1.3B
935.06M
425.21M
339.41M
586.89M
353.36M
237.51M
200.65M
709.54M
581.7M
187.69M
138.76M
344.9M
545.51M
263.78M
142.96M
77.71M
311.68M
44.97M
32.79M
267.19M
233.83M
218.82M
110.17M
141.74M
100.24M
68.42M
40.9M
125.46M
133.58M
150.4M
69.27M
0
-1.7M
-7.35M
2.2M
364.64M
-13.44M
-76.09M
-4.2M
46.3M
-9.48M
-14.21M
-7.28M
410.94M
26.72M
-75.04M
-11.48M
84.28M
-1.35M
-3.76M
1.99M
326.66M
28.07M
-71.28M
-13.47M
4.79
0.41
-1.06
-0.25
4.65
0.4
-1.06
-0.25
68.27M
68.49M
67.49M
54.13M
70.24M
70.67M
67.49M
54.13M
491M
81.83M
-25M
22.69M
2023
2022
2021
2020
-193.16M
-221.22M
-149.95M
-136.47M
326.66M
28.07M
-71.28M
-13.47M
0
-75M
0
0
0
0
0
0
133.5M
-193.16M
-221.22M
-149.95M
326.66M
-46.93M
-71.28M
-13.47M
2023
2022
2021
2020
192.02M
122.17M
116.77M
120.17M
60.04M
47.93M
42.29M
24.69M
-46.55M
-18.35M
-12.14M
-12.47M
178.53M
92.58M
86.62M
107.96M
2023
2022
2021
2020
0
0
2.56M
42.92M
61.19M
61.19M
58.63M
15.71M
61.19M
61.19M
61.19M
58.63M
All figures are in USD.